This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

WCLC - Tsao Presentation

LUME-Meso Phase II/III study: nintedanib + pemetrexed/cisplatin in chemotherapy-naïve patients with malignant pleural mesothelioma

Tsao A, Vogelzang N, Nowak A, Popat S, Gaafar R, van Meerbeeck J, Nakano T, Barrueco J, Morsli N, Scagliotti G

RELATED ARTICLES

Learn more about the science behind this poster in the papers and other materials below

 

Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled LUME-Meso trial

Grosso F et al. JCO 2017; DOI: 10.1200/JCO.2017.72.9012

LUME-Meso: design and rationale of the Phase III part of a placebo-controlled study of nintedanib and pemetrexed/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma

Scagliotti G et al. CLC 2017; DOI: 10.1016/j.cllc.2017.03.010

Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.